Jason Karp Hates MannKind Corporation (MNKD), Likes NCR Corporation, Ctrip.com International, Ltd. (ADR) (CTRP)
According to CNBC, Tourbillon Capital's Jason Karp is betting on a decline of MannKind Corporation (NASDAQ:MNKD) shares.
Posts Tagged ‘NASDAQ:MNKD’
Nektar Therapeutics (NKTR), Pfizer Inc. (PFE): What’s MannKind Corporation (MNKD) Really Worth?
This is close to the market cap that Bank of America's Steve Byrne thinks MannKind Corporation (NASDAQ:MNKD) is worth.
MannKind Corporation (MNKD), Seattle Genetics, Inc. (SGEN), Eli Lilly & Co. (LLY): A Pharmacology Primer for Biotech Investors
In pharmacology, we don't only have to consider the actions of the drug on the body.
MannKind Corporation (MNKD), Pfizer Inc. (PFE): Why Afrezza May Not Work
MannKind Corporation (NASDAQ:MNKD) has been struggling to get its inhalable insulin product Afrezza on the market; the product was sent back to the labs by the Food and Drug Administration...
MannKind Corporation (MNKD) News: Healthcare Conference, Executives, FAQ list & More
MannKind Corporation, focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at The Morgan Stanley Global Healthcare...
Hedge Funds Are Betting On Celldex Therapeutics, Inc. (CLDX)
If you were to ask many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Here is What Hedge Funds and Insiders Think About Puma Biotechnology Inc (PBYI)
In today’s marketplace, there are dozens of methods market participants can use to watch the equity markets.
Will This Destroy MannKind Corporation (MNKD)?
The drug more closely mimics how the body secretes insulin after a meal to lower blood sugar, doing its job and leaving the bloodstream quickly.
Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Announcement & MannKind Corporation (MNKD)’s New Options
This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
MannKind Corporation (MNKD), EXCO Resources Inc (XCO), Riverbed Technology, Inc. (RVBD): What This $18B Scandal-Ridden Hedge Fund Has Been Buying
Today, let's look at SAC Capital Advisors, run by Steven Cohen.
MannKind Corporation (MNKD): To Infinity And Beyond?
The idea inspired me to issue my own questions about the company, using the questions as a crutch to explain my position.
NPS Pharmaceuticals, Inc. (NPSP): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In today’s marketplace, there are tons of gauges market participants can use to track their holdings.
MannKind Corporation (MNKD), Incyte Corporation (INCY): Will This Large Biotech Pop Experience Analyst Backlash?
While I do think it's possible that MannKind Corporation (NASDAQ:MNKD)'s inhaled insulin device, Afrezza, will be approved by the Food and Drug Administration, I do have serious...
What Hedge Funds Think About VIVUS, Inc. (VVUS)
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market.
This MannKind Corporation (MNKD) Data Is Simply Jaw-Dropping. Wow.
MannKind Corporation (NASDAQ:MNKD) has gotten one of the biggest votes of confidence we've seen from the smart money, out of the entire stock market universe and the 500+ elite...
MannKind Corporation (MNKD) Highlights: Second Tranche of Financing, Upward Trend, Price Target & More
The MannKind Corporation has announced that as per the agreement to the 1 July 2013, facility contract, between MNKD and the Deerfield Private Design Fund II.
AstraZeneca plc (ADR) (AZN), Eli Lilly & Co. (LLY), MannKind Corporation (MNKD): Three New Diabetes Drugs Possibly on the Way Soon
It's no wonder that plenty of companies are developing diabetes drugs. There are more than 370 million people with diabetes worldwide.
MannKind Corporation (MNKD), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS) – Attention Biotech Investors: Stop Looking at Share Price
After my article on MannKind Corporation (NASDAQ:MNKD) earlier this week, a reader wasn't too happy about my view that the company was overvalued given the most recent phase ...
Osiris Therapeutics, Inc. (OSIR), GlaxoSmithKline plc (ADR) (GSK), Forest Laboratories, Inc. (FRX): This Week in Biotech
With the SPDR S&P Biotech Index up 34% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Merrimack Pharmaceuticals Inc (MACK), MannKind Corporation (MNKD), Synta Pharmaceuticals Corp. (SNTA): Horrendous Health-Care Stocks This Week
While the major indexes pulled back this week, their declines paled in comparison to the huge drops experienced by a handful of health-care stocks.
Orbitz Worldwide, Inc. (OWW), Vical Incorporated (VICL), MannKind Corporation (MNKD): Last Week’s Biggest Losers
Let's start with Vical Incorporated (NASDAQ:VICL). The biotech shed more than half of its value after abandoning its once promising Allovectin program.
Netflix, Inc. (NFLX), Microsoft Corporation (MSFT): This Week’s Smartest Stock Moves
Yum! Brands, Inc. (NYSE:YUM)'s Taco Bell is keeping the Doritos-dusted taco shells coming.
MannKind Corporation (MNKD) Latest News: $40M Financing for Afrezza, Rating Reiterated by Zacks, Price Target & More
MannKind's positive take on interim Phase III data for its inhaled insulin Afrezza has a big sweetener tied to it.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): Dreamboat Data? Not Exactly.
MannKind Corporation (NASDAQ:MNKD) ended up more than 10% on Wednesday, after the biotech announced positive results for two phase 3 trials testing its inhaled insulin Afrezza...
MannKind Corporation (MNKD): What’s the Latest: New Insulin Inhaler, Rating Reiterated by Zacks, Matthew J. Pfeffer & More
The long promise of insulin that diabetics can inhale appears to be moving closer to the market.
MannKind Corporation (MNKD), Eli Lilly & Co. (LLY): The Easiest Prediction in Biotech This Summer
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive.
MannKind Corporation (MNKD), Novo Nordisk A/S (ADR) (NVO), Eli Lilly & Co. (LLY): A Good Drug That’s Too Risky to Buy
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)'s extended phase 3 program for its inhaled insulin, Afrezza, is likely to produce ...
MannKind Corporation (MNKD) News: FDA Approval, Cloud Hosting & More
With luck, Santa Clarita’s MannKind Corporation (NASDAQ:MNKD) hopes to have FDA approval by April of next year of its innovative diabetes treatment – Afrezza.
ExOne Co (XONE), MannKind Corporation (MNKD): Here’s What This $30 Billion Pension Fund Has Been Buying
Today, let's look at the California State Teachers' Retirement System ("CalSTRS"), a major pension fund that's celebrating its 100th anniversary in 2013.
Elan Corporation, plc (ADR) (ELN), VIVUS, Inc. (VVUS), MannKind Corporation (MNKD): Three Biotech Companies to Watch This Summer
The news flow from biotech companies might slow down during the summer, but it won't stop.
Who Really, Really Wants Some More Pfizer Inc. (PFE) Stock?
An entity with deep pockets is looking to buy boatloads of Pfizer Inc. (NYSE:PFE) stock. And we're talking yacht-sized boatloads -- not canoe-sized ones.
Tesla Motors Inc (TSLA) & Other Surprises That Are Beating Netflix, Inc. (NFLX) in 2013
Netflix, Inc. (NASDAQ:NFLX) has been a poster boy for market success in 2013.
MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
MannKind Corporation (MNKD) News: Study 175 n=353 Update, Hyperglycemia & More
The share prices of MannKind Corporation (NASDAQ:MNKD) had been traded in the price range of $5.70 and $7.62 per share on Tuesday.
Microsoft Corporation (MSFT), QUALCOMM, Inc. (QCOM): The Dow’s Triple-Digit Gains Left These Stocks Behind
Investors can never predict whether the market will rise or fall on any given day, but lately, a pretty good bet has been to expect some substantial volatility in one direction...
Why MannKind Corporation (MNKD) Is Poised to Pull Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company MannKind Corporation...
Bristol Myers Squibb Co (BMY), Momenta Pharmaceuticals, Inc. (MNTA): White Collar Criminals Love Biotech Stocks
It's understandably very tempting for people with inside information to trade biotech stocks.
MannKind Corporation (MNKD) Still Treading Water, So Why Are Investors Surfing?
You could say that MannKind Corporation (NASDAQ:MNKD) is treading water a bit these days -- at least from the outside perspective.
MannKind Corporation (MNKD): Are Hedge Funds Right About This Stock?
According to most stock holders, hedge funds are viewed as underperforming, old financial vehicles of the past.
MannKind Corporation (MNKD), Sarepta Therapeutics Inc (SRPT): Why You Shouldn’t Buy Stocks in Biotech
How can you double your investment literally overnight? Buy stocks of the right biotech companies.
Here is What Hedge Funds Think About Puma Biotechnology Inc (PBYI)
In the eyes of most traders, hedge funds are seen as worthless, old financial tools of the past.
Do Hedge Funds and Insiders Love Celldex Therapeutics, Inc. (CLDX)?
In the financial world, there are plenty of indicators market participants can use to track publicly traded companies.
Aegerion Pharmaceuticals, Inc. (AEGR), MannKind Corporation (MNKD): 3 Biotech Companies You Should Have Bought This Year
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Santarus, Inc. (SNTS): Insiders Are Buying, Should You?
If you'd ask most shareholders, hedge funds are assumed to be underperforming, old investment tools of the past.
NPS Pharmaceuticals, Inc. (NPSP): Hedge Funds and Insiders Are Bearish, What Should You Do?
If you'd ask most shareholders, hedge funds are assumed to be slow, outdated investment tools of the past.
MannKind Corporation (MNKD)’s Run to Glory
Shares of MannKind Corporation (NASDAQ:MNKD) have nearly tripled over the last year.
MannKind Corporation (MNKD), PDL BioPharma Inc. (PDLI) & Optimer Pharmaceuticals, Inc. (OPTR): 2 Biotechs to Avoid, 1 to Buy
Keeping a close eye on two particular classes of investors can tell you a lot about how stocks might move in the future.
MannKind Corporation (MNKD) News: Substantial Take Off, Zacks Score and More
An enormous call trade tops today's option activity in biopharmaceutical company MannKind Corporation (NASDAQ:MNKD) as takeover speculation rises.
